title: Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
abstract: Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established. A total 60 patients with ACS were divided into three groups; receiving aspirin, clopidogrel and aspirin-clopidogrel combination. For determination of renal function, serum BUN, creatinine, uric acid, uric acid clearance and GFR were estimated for four months. The study showed that there were no significant (p>0.05) variations in the parameters when used the drugs in combination (aspirin-clopidogrel) compared with the drugs given alone.
authors.affiliation: Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan / Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
authors.forename: Muhammad Imran
authors.initials: MI
authors.lastname: Qadir
authors.affiliation: Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
authors.forename: Attaur
authors.initials: A
authors.lastname: Rehman
authors.affiliation: Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
authors.forename: Muhammad Sajid
authors.initials: MS
authors.lastname: HamidAkash
authors.affiliation: Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Irfan
authors.affiliation: Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Baber
authors.affiliation: Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
authors.forename: Syed Bilal
authors.initials: SB
authors.lastname: Hussain
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D000077144:Clopidogrel; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood
chemical_list: D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D014527:Uric Acid; D000077144:Clopidogrel; D003404:Creatinine; D013988:Ticlopidine; D001241:Aspirin